Showing 2511-2520 of 6036 results for "".
- EssilorLuxottica Acquires Espansione Group, Provider of Noninvasive Ophthalmic Medical Deviceshttps://modernod.com/news/essilorluxottica-acquires-espansione-group-provider-of-noninvasive-ophthalmic-medical-devices/2482581/Optical giant EssilorLuxottica announced it is acquiring Italy-based Espansione Group, a provider of noninvasive medical devices for the diagnosis and treatment of dry eye, ocular surface and retinal diseases. Financial terms of the deal were not disclosed. Esp
- Nicox’s Denali Phase 3 Trial of NCX 470 Fully Enrolled in Chinahttps://modernod.com/news/nicoxs-denali-phase-3-trial-of-ncx-470-fully-enrolled-in-china/2482561/Nicox announced that its Denali phase 3 trial evaluating the efficacy and safety of NCX 470 in patients with open-angle glaucoma or ocular hypertension is now fully enrolled in China and screening has been closed. Completion of recruitment of patients in the
- Alkeus Secures Rare Pediatric Disease and Fast Track FDA Designations for Gildeuretinol in Stargardt Diseasehttps://modernod.com/news/alkeus-secures-rare-pediatric-disease-and-fast-track-fda-designations-for-gildeuretinol-in-stargardt-disease/2482549/Alkeus Pharmaceuticals announced that its investigational oral therapy, gildeuretinol (ALK-001), has been granted Rare Pediatric Disease and Fast Track designations by the FDA for the treatment of Stargardt disease. “Stargardt disease imposes a relentless burden, robbing chil
- MediPrint Ophthalmics Unveils Phase 2b Trial Results for Drug-Eluting Contact Lens in Glaucoma Treatmenthttps://modernod.com/news/mediprint-ophthalmics-unveils-phase-2b-trial-results-for-drug-eluting-contact-lens-in-glaucoma-treatment/2482539/MediPrint Ophthalmics announced positive results from its phase 2b clinical trial of its 3D-printed, drug-eluting contact lens LL-BMT1. The results, presented by Ian Ben Gaddie, OD, FAAO, at the Ameri
- Johnson & Johnson Presents New Data on ACUVUE OASYS MAX 1-Day Contact Lenseshttps://modernod.com/news/johnson-johnson-presents-new-data-on-acuvue-oasys-max-1-day-contact-lenses/2482523/Johnson & Johnson will present data at Academy of Optometry 2024 on the ACUVUE OASYS MAX 1-Day family of contact lenses including contrast sensitivity, brightness of natural images, lens handling, and more. Data will also be presented on myopia management, use of digital technologie
- GenSight Biologics Publishes Meta-Analysis on Efficacy of Treatments for Leber Hereditary Optic Neuropathyhttps://modernod.com/news/gensight-biologics-publishes-meta-analysis-on-efficacy-of-treatments-for-leber-hereditary-optic-neuropathy/2482521/GenSight Biologics announced the publication of a meta-analysis evaluating visual outcomes in patients with Leber Hereditary Optic Neuropathy (LHON) due to the MT-ND4 mitochondrial gene mutation. This mutation, known as ND4-LHON, is the most common cause of the disease and is associated with the
- Study of Alkeus' Oral Gildeuretinol Demonstrate Trend in Slowing GA Progression and Visual Function Improvementhttps://modernod.com/news/study-of-alkeus-oral-gildeuretinol-demonstrate-significant-trend-in-slowing-ga-progression-and-visual-function-improvement/2482511/Alkeus Pharmaceuticals announced findings from its SAGA study, which evaluated the investigational oral therapy gildeuretinol (ALK-001) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The study showed a statistically significant reduction in GA l
- SpyGlass Pharma Unveils Promising 18-Month Data from First-in-Human Study of Glaucoma Drug Delivery Platformhttps://modernod.com/news/spyglass-pharma-unveils-promising-18-month-data-from-first-in-human-study-of-glaucoma-drug-delivery-platform/2482500/SpyGlass Pharma presented 18-month follow-up data today from its first-in-human study of patients with glaucoma or ocular hypertension. The study evaluated the efficacy of the SpyGlass IOL-based drug delivery platform, which was implanted during cataract surgery. The results were shared at Eyecel
- AAO: Home OCT Device Improves Care for AMD Patients, Reduces Costs and Burdenhttps://modernod.com/news/aao-home-oct-device-improves-care-for-amd-patients-reduces-costs-and-burden/2482499/A newly approved home-based OCT device developed by Notel Vision is allowing patients to monitor their own eye health between appointments, providing physicians with crucial data without requiring in-office visits, according to an AAO news release. A study presented today at AAO 2024 suggest
- Alcon Collaborates with Eye Care Professionals to Identify and Address Unmet Needs in the Contact Lens Industryhttps://modernod.com/news/alcon-collaborates-with-eye-care-professionals-to-identify-and-address-unmet-needs-in-the-contact-lens-industry/2482485/A new Alcon program aims to identify and address current gaps in contact lens offerings by partnering with eye care professionals. With the new Alcon Innovator Program, 20 ‘innovators’ were selected to receive and offer their patients exclusive access to Alcon’s upcoming product